UNICYCIVE THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Increase Decrease In Operating Lease Liability of -$355.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$144.00K.
- UNICYCIVE THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$211.00K.
- UNICYCIVE THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$148.00K.
- UNICYCIVE THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$144.00K.
- UNICYCIVE THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$565.00K.
- UNICYCIVE THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$397.00K.
- UNICYCIVE THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$252.00K.
- UNICYCIVE THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$151.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$355.00K 10-Q · filed 2026-08-12 | -$503.00K derived: sum of 3 quarters · filed 2026-08-12 | -$647.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$211.00K 10-Q · filed 2026-05-12 | -$359.00K derived: sum of 2 quarters · filed 2026-05-12 | -$503.00K derived: sum of 3 quarters · filed 2026-05-12 | -$643.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$292.00K derived: sum of 2 quarters · filed 2026-03-30 | -$432.00K derived: sum of 3 quarters · filed 2026-08-12 | -$565.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$144.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$284.00K derived: sum of 2 quarters · filed 2026-08-12 | -$417.00K 10-Q · filed 2025-11-12 | -$543.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$273.00K 10-Q · filed 2026-08-12 | -$399.00K derived: sum of 3 quarters · filed 2026-08-12 | -$512.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$133.00K 10-Q · filed 2026-05-12 | -$259.00K derived: sum of 2 quarters · filed 2026-05-12 | -$372.00K derived: sum of 3 quarters · filed 2026-05-12 | -$257.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$239.00K derived: sum of 2 quarters · filed 2026-03-30 | -$124.00K derived: sum of 3 quarters · filed 2026-03-30 | -$397.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.00K derived: sum of 2 quarters · filed 2025-11-12 | -$271.00K 10-Q · filed 2025-11-12 | -$344.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$158.00K 10-Q · filed 2025-08-14 | -$231.00K derived: sum of 3 quarters · filed 2025-08-14 | -$303.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$273.00K 10-Q · filed 2025-05-14 | -$346.00K derived: sum of 2 quarters · filed 2025-05-14 | -$418.00K derived: sum of 3 quarters · filed 2025-05-14 | -$471.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$145.00K derived: sum of 2 quarters · filed 2025-03-31 | -$198.00K derived: sum of 3 quarters · filed 2025-03-31 | -$252.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$125.00K derived: sum of 2 quarters · filed 2024-11-13 | -$179.00K 10-Q · filed 2024-11-13 | -$219.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$107.00K 10-Q · filed 2024-08-14 | -$147.00K derived: sum of 3 quarters · filed 2024-08-14 | -$185.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$54.00K 10-Q · filed 2024-05-13 | -$94.00K derived: sum of 2 quarters · filed 2024-05-13 | -$132.00K derived: sum of 3 quarters · filed 2024-05-13 | -$169.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$78.00K derived: sum of 2 quarters · filed 2024-03-28 | -$115.00K derived: sum of 3 quarters · filed 2024-03-28 | -$151.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$75.00K derived: sum of 2 quarters · filed 2023-11-14 | -$111.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$73.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$36.00K 10-Q · filed 2023-05-16 | |||
| 2021-12-31 | -$12.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |